Deutsche Bank Downgrades ABIOMED (ABMD) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Price: $381.02 --0%
Rating Summary:
7 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
7 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
Deutsche Bank analyst Pito Chickering downgraded ABIOMED (NASDAQ: ABMD) from Buy to Hold with a price target of $388.00 (from $355.00).
For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.
Shares of ABIOMED closed at $377.82 yesterday.
You May Also Be Interested In
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
- Rede D`Or Sao Luiz SA (RDOR3:BZ) PT Lowered to BRL44 at UBS
- Rosenblatt cuts Roku to Neutral as Fox merger nears closing
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
